Syngene is devoted to keeping industry professionals abreast of the latest development and most topical news that takes place within the organization. Proactive sharing also helps our stakeholders to stay informed, which creates greater value for themselves and the organization.
May - 2018
Syngene International Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services
Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterize novel antibody clones...
Apr - 2018
Syngene Delivers Strong Revenue Momentum
Strong Q4 FY18 revenue of Rs 426 Cr (+35%) brings full-year revenue to Rs 1485 Cr (+17%) Signs strategic discovery partnership with GSK.
Mar - 2018
Syngene International Signs R&D Agreement with GSK
Syngene scientists to work with GSK to advance drug discovery in multiple therapeutic areas.
Jan - 2018
Syngene Q3 FY18 Revenue up 15% to Rs. 399 Cr
During the Quarter, extends collaboration with BMS until 2026; Signs strategic collaboration with Zoetis.
Nov - 2017
Bristol-Myers Squibb and Syngene International Expand Ongoing Research Collaboration
Scope of partnership expanded, including additional research capacity.
Oct - 2017
Syngene Growth Picks Up in Q2 FY18
Revenue up 10% to Rs 352 Cr; EBITDA up 7% to Rs 130 Cr.
Jul - 2017
Syngene Q1 FY18 Revenue up 6% to Rs. 308 Cr
Syngene International Limited- Q1 FY 2017-18 -Press Release.
Jul - 2017
Syngene International Announces Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center
With the expansion, the floor space of SARC will double to 50,000 sq. ft. A team of up to 185 multi-disciplinary Syngene scientists will work at SARC.
Apr - 2017
Syngene Delivers 14% Revenue Growth in FY17
Syngene International Limited- Q4 FY 2016-17 -Press Release.
Mar - 2017
Herbalife Nutrition Partners with Syngene to Establish Nutrition Research and Development Lab in India
The new Nutrition Research and Development facility spans 3,000 sq ft, and is located within the Syngene campus at Bangalore. -Press Release.
Jan - 2017
Syngene Q3 Revenue up by 23%
Syngene International Limited- Q3 FY 2016-17 -Press Release.
Dec - 2016
Fire Incident at Syngene Facility
No Injuries or Loss of Life; BCP activated to minimize impact on Operations -Press Release.
Oct - 2016
Syngene registers strong top and bottom line growth in Q2 FY17
Syngene International Limited- Q2 FY 2016-17 -Press Release.
Sep - 2016
Syngene International closes deal with Strand Life Sciences to Purchase Systems Biology and Pharma Services Practice
Syngene has purchased assets of Strand Life Sciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team -Press Release.
Sep - 2016
Syngene International Commissions Dedicated R&D Center for Amgen
Syngene International, one of Asia’s largest R&D focused contract research organization, today announced the establishment in Bangalore, India, of an integrated, multi-disciplinary drug discovery and development center for Amgen -Press Release.
Jul - 2016
Syngene’s Robust Growth Continues in Q1 FY17
Syngene International Limited- Q1 FY 2016-17 -Press Release.
Apr - 2016
Syngene delivers sustained growth in Q4 FY16
Syngene International Limited- Q4 FY 2015-16 -Press Release.
Jan - 2016
Syngene growth momentum continues with robust Q3 FY16 delivery
Syngene International Limited- Q3 FY 2015-16 -Press Release.
Jan - 2016
Syngene appoints Jonathan Hunt as CEO-designate
Syngene International Limited, one of Asia’s largest Contract Research Organizations, today announced the appointment of Jonathan Hunt as CEO-designate. Mr Hunt will take charge as CEO post the retirement of current CEO Peter Bains in March 2016.
Oct - 2015
Syngene delivers broad based growth of 28% in H1 FY16
Syngene International Limited- Q2 and H1 FY16 Press Release.
Aug - 2015
Syngene International lists at Rs 295 on BSE; NSE; closes at a premium of 24% at Rs 310.55 on Listing day
Syngene International Limited (“Syngene”), listed today on the Indian capital markets at Rs. 295 on BSE & NSE. The stock has recorded a high of Rs 318.50 and a low of Rs 295 on the listing day on NSE, while its touched a high of Rs 318.20 and a low of Rs 295 on BSE.
Jul - 2015
Syngene International IPO oversubscribed 31 times
Syngene International Limited (“Syngene”) today announced that its Initial Public Offering (IPO) has been oversubscribed 31 times based on the electronic bid file available on the websites of Stock Exchanges at 8.00 pm.
Jul - 2015
Syngene International gets RoC approval for its RHP
Syngene International Ltd (“Syngene” or the “Company”) today announced that it has obtained the approval of the Registrar of Companies (RoC) for its Red Herring Prospectus, for an Initial Public Offering (IPO).
Sep - 2014
Silver Leaf Oak acquires 10% stake in Syngene International, Biocon’s Research Services Subsidiary
Silver Leaf Oak (Mauritius) Limited ("Silver Leaf"), an investment vehicle advised by India Value Fund Advisors
("IVFA") has agreed to acquire a minority 10% stake in Syngene International Limited ("Syngene"), Biocon's
Research Services subsidiary.
Jun - 2014
Bristol-Myers Squibb and Syngene International Extend Research Collaboration
(PRINCETON, N.J. and BANGALORE, INDIA – June 3, 2014) – Bristol-Myers Squibb (NYSE: BMY) and
Syngene International, India’s largest contract research organization, today announced a five-year extension of
their drug discovery and development collaboration in India.
Feb - 2014
Shri Ghulam Nabi Azad Inaugurates Baxter Global Research Center at Syngene
Syngene, India's leading contract research organization and Baxter International Inc., a leading global
pharmaceutical company have collaborated to establish the Baxter Global Research Center at Syngene, in
Oct - 2012
GE Capital to invest in Syngene, Biocon’s Research Services Subsidiary
Biocon, Asia's premier biotechnology Company, announced today that it has signed an agreement with GE
Equity International Mauritius, a subsidiary of GE Capital Corporation ("GE Capital"), which will make a
primary equity investment in its research services subsidiary, Syngene International Limited (Syngene).
Jun - 2012
Abbott inaugurates First Nutrition Research and Development Center in India in collaboration with Syngene
Abbott, one of India's largest healthcare companies, today inaugurated its first nutrition research and
development center in the country, in collaboration with Syngene, India's leading contract research organization.
Jul - 2011
Syngene and Endo to expand their collaboration in cancer research
Syngene International, a subsidiary of Biocon Ltd, the Indian biotechnology major, and Endo Pharmaceuticals
USA (NASDAQ: ENDP) announced today that they have signed an agreement to expand their collaboration to
develop novel biological therapeutic molecules against cancer.
Mar - 2009
Syngene and DuPont Crop Protection Forge Alliance Partnership
Syngene International, a subsidiary of BIOCON Ltd, Indian biotechnology major, announced today its
agreement as alliance partner with DuPont Crop Protection.
Jan - 2009
Syngene partners with Sapient Discovery to expand integrated drug discovery offerings
Syngene International, a subsidiary of BIOCON Group, Indian biotechnology major, announced today that it
will offer fully integrated drug discovery services by partnering with Sapient Discovery, a US based
Mar - 2007
Biocon's Syngene enters into research partnership with Bristol-Myers Squibb
Biocon Limited, India's premier biotechnology company today announced that its subsidiary company Syngene
has entered into a research partnership with Bristol-Myers Squibb (NYSE: BMY).
Sep - 2006
Syngene International and Innate Pharmaceuticals collaborate to develop virulence blockers
Syngene International Private Limited, a wholly owned subsidiary of Biocon Limited and Innate
Pharmaceuticals AB, Umea, Sweden have concluded a cooperation agreement to jointly develop, manufacture
and market virulence blockers to counteract bacterial diarrhoeal disease.
Aug - 2004
Syngene enters into research agreement with Novartis Institute for Biomedical Research Inc.
Biocon's subsidiary, Syngene International, announced that it has entered into a contract research agreement
with the Novartis Institutes for Biomedical Research, Inc. to carry out research projects to support new drug
discovery and development.